<DOC>
	<DOC>NCT01529307</DOC>
	<brief_summary>This study will assess safety, tolerability, maximum tolerated dose or recommended dose for expansion of TAS266 administered by IV infusion to patients with advanced solid tumors.</brief_summary>
	<brief_title>First in Human Trial of TAS266 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Confirmed diagnosis of solid tumors 18 years or older ECOG performance status of 0, 1 or 2 Adequate bone marrow, hepatic and renal function Obtained written informed consent Patients with primary CNS tumor or CNS tumor involvement. However patients with CNS metastases may be allowed if certain conditions are met. Major surgery within 4 weeks before study treatment Prior anaphylactic or other severe infusion reactions to human immunoglobulin or antibody formulations Impaired cardiac functions Previous hepatitis viral infection such as hepatitis B or hepatitis C Diagnosis of HIV infection Pregnant or nursing (lactating) women Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>Biologic,</keyword>
	<keyword>solid tumors,</keyword>
	<keyword>Death Receptor 5 agonist,</keyword>
	<keyword>caspase-8</keyword>
</DOC>